ポスト

🚨 Upcoming catalyst for $SNDX ! Their lead candidate, Revumenib, faces a pivotal FDA decision on Dec 26, 2024. With a solid cash runway till 2026, the potential approval could be a game-changer for R/R KMT2Ar leukemia patients. 💊 #Biotech #FDA #SNDX See more from SNDX:… https://t.co/xafJX3K6Al

メニューを開く

BioPharmCatalyst@BPharmCatalyst

人気ポスト

もっと見る
Yahoo!リアルタイム検索アプリ